09/03/2008 – Madeira is pleased to announce the newest addition to their Board of Advisors.
Madeira Therapeutics, a new drug-development company specializing in pediatric pharmaceuticals, is pleased to announce the addition of David L. Tousley, MBA, CPA, to the Madeira Board of Advisors. David Tousley is currently the Principal of Stratium Consulting Services, assisting companies with strategic and financial planning and management.
Tousley will provide the Madeira Board of Advisors with over 25 years of business experience through his impressive professional achievements in all aspects of financial, pharmaceutical development and process management. Tousley is also a director of Immunogenetix Therapeutics, Inc. and Anavex Life Sciences Corp.
According to Madeira CEO Peter Joiner, "Dave is a superb addition to our Board; he brings expertise in corporate governance, finance and pediatric drug development. Madeira has just completed its seed funding. Dave's experience and financial contacts will enable us to promptly complete the next round of funding. We are fortunate to have him join the team."
Prior to joining the Madeira Board of Advisors, Tousley also held president, chief operating officer and chief financial officer roles in airPharma, LLC; PediaMed Pharmaceuticals, Inc.; AVAX Technologies, Inc.; and Pasteur, Merieux, Connaught (known today as Sanofi-Pasteur). He has managed in both the private and public company environment – taking a company public and raising over 90 million dollars in debt and equity financings. He holds an undergraduate degree from Rutgers College and earned his MBA in accounting from Rutgers Graduate School.